Nazli Dizman MDResident, Internal Medicine, Yale School of Medicine, Yale New Haven Hospital, New Haven, Connecticut
Dr. Nazli Dizman is an internal medicine resident at Yale School of Medicine, Yale New Haven Hospital. Prior to joining Yale, she graduated from Ege University School of Medicine in Izmir, Turkey and completed her internal medicine residency training at Istanbul Medeniyet University School of Medicine in Istanbul, Turkey. She worked as a postdoctoral fellow in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center in Duarte, California between 2016 and 2020.
Dr. Dizman has been involved in clinical and translational research projects in the area of genitourinary cancers since 2016. She has played crucial roles in the planning, initiation and management of several clinical and translations studies examining the role of clinical factors, genomics, and the microbiome on clinical outcomes in genitourinary cancers. Dr. Dizman has published over 40 peer-reviewed articles in scientific journals and presented several abstracts at national and international meetings.
DisclosuresConsultation fees from Vivreon Gastroscience Inc.
Recent Contributions to PracticeUpdate:
- Clear Cell Renal Cell Carcinoma With Sarcomatoid Dedifferentiation in Patient With HIV
- Metastatic Renal Cell Carcinoma Patient With Indolent Disease
- Management of Rare RCC Subtypes—Chromophobe Renal Cell Carcinoma
- Management of Rare RCC Subtypes - Translocation RCC
- Management of Rare RCC Subtypes - Renal Medullary Carcinoma
- Systemic Therapy for mRCC Patient on Hemodialysis
- Genetics Consultation in RCC Patient
- ASCO: Cabozantinib and Atezolizumab in Urothelial Cancer
- ASCO: Early Data on the Gut Microbiome and Outcomes in RCC
- Progression After Immunotherapy in Patient With Recurrent RCC